Literature DB >> 25846865

Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion.

Esther P Verduin1,2, Anneke Brand2, Rutger A Middelburg1,3, Henk Schonewille4.   

Abstract

BACKGROUND: More women than men are encountered with red blood cell (RBC) antibodies. It is not clear whether this difference is explained by more immunizing events in women or by a different acting immune system. To assess whether there is a difference in the posttransfusion RBC alloimmunization rate between women and men, a study on RBC alloimmunization during a 5-year period was conducted in patients with at least one antibody follow-up more than 14 days after transfusion. STUDY DESIGN AND METHODS: Data on transfusion and antibody follow-up characteristics in female and male transfusion recipients from the Leiden University Medical Center laboratory database were collected. Hazard ratios of alloimmunization, according to sex of the transfusion recipient, were estimated using Cox proportional hazards regression models taking possible confounders into account.
RESULTS: From a total of 1699 women and 1969 men who were eligible, 4.2% of women and 3.4% of men (relative risk, 1.3; 95% confidence interval [CI], 0.9-1.8) developed posttransfusion antibodies. Adjustment for confounders resulted in a relative 80% higher risk in women older than 45 years of age.
CONCLUSION: Elder women beyond childbearing age have a higher risk of posttransfusion antibody formation compared to men.
© 2015 AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25846865     DOI: 10.1111/trf.13111

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.

Authors:  Sebastián Ortiz; Maria T Orero; Karla Javier; Carolina Villegas; Irene Luna; Pedro Pérez; Mónica Roig; María López; Sofía Costa; Félix Carbonell; Rosa Collado; David Ivars; Mariano Linares
Journal:  Blood Transfus       Date:  2016-06-24       Impact factor: 3.443

2.  Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.

Authors:  Matthew S Karafin; Matt Westlake; Ronald G Hauser; Christopher A Tormey; Philip J Norris; Nareg H Roubinian; Yanyun Wu; Darrell J Triulzi; Steve Kleinman; Jeanne E Hendrickson
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

3.  A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study.

Authors:  Johanne Rozema; Christiaan L Slim; Nic J G M Veeger; Robby E Kibbelaar; Harry de Wit; Eric N van Roon; Mels Hoogendoorn
Journal:  Blood Transfus       Date:  2020-12-16       Impact factor: 3.443

4.  The Rh blood group system and its role in alloimmunization rate among sickle cell disease and sickle thalassemia patients in Iran.

Authors:  Mohammad Ali Jalali Far; Arezoo Oodi; Naser Amirizadeh; Mahshid Mohammadipour; Bijan Keikhaei Dehdezi
Journal:  Mol Genet Genomic Med       Date:  2021-02-06       Impact factor: 2.183

5.  The effect of extended c, E and K matching in females under 45 years of age on the incidence of transfusion-induced red blood cell alloimmunisation.

Authors:  Josine A Oud; Dorothea Evers; Masja de Haas; Karen M K de Vooght; Daan van de Kerkhof; Nel Som; Nathalie C V Péquériaux; Francisca Hudig; Arjan Albersen; Johanna G van der Bom; Jaap Jan Zwaginga
Journal:  Br J Haematol       Date:  2021-08-03       Impact factor: 8.615

6.  A Conceptual Framework for Optimizing Blood Matching Strategies: Balancing Patient Complications Against Total Costs Incurred.

Authors:  Joost H J van Sambeeck; Puck D de Wit; Jessie Luken; Barbera Veldhuisen; Katja van den Hurk; Anne van Dongen; Maria M W Koopman; Marian G J van Kraaij; C Ellen van der Schoot; Henk Schonewille; Wim L A M de Kort; Mart P Janssen
Journal:  Front Med (Lausanne)       Date:  2018-07-25

7.  Retrospective Study on Prevalence, Specificity, Sex, and Age Distribution of Alloimmunization in Two General Hospitals in Athens

Authors:  Marianna Politou; Serena Valsami; Georgios Dryllis; Maria Christodoulaki; Christina Cheropoulou; Abraham Pouliakis; Maria Baka; Konstantinos Stamoulis
Journal:  Turk J Haematol       Date:  2020-04-22       Impact factor: 1.831

8.  Red Blood Cell Alloimmunization in Korean Patients With Myelodysplastic Syndrome and Liver Cirrhosis.

Authors:  Hyun Young Kim; Eun Jung Cho; Sejong Chun; Kyeong Hee Kim; Duck Cho
Journal:  Ann Lab Med       Date:  2019-03       Impact factor: 3.464

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.